Osteoclast-mediated bone destruction is amplified in the hypoxic synovial microenvironment of
rheumatoid arthritis (RA). This increased
bone resorption is driven by the
hypoxia-inducible
transcription factor HIF. We identified hypoxic induction of the HIF-regulated
adenosine A2B receptor in primary human osteoclasts (
mRNA, 3.8-fold increase, p < 0.01) and sought to identify the role(s) of purinergic signaling via this receptor in the
bone resorption process. Primary human osteoclasts were differentiated from CD14+ monocytes and exposed to
hypoxia (2% O2) and A2B receptor inhibitors (
MRS1754,
PSB603). The hypoxic increase in
bone resorption was prevented by the inhibition of the A2B receptor, at least partly by the attenuation of glycolytic and mitochondrial metabolism via inhibition of HIF. A2B receptor inhibition also reduced osteoclastogenesis in
hypoxia by inhibiting early cell fusion (day 3-4, p < 0.05). The A2B receptor is only functional in hypoxic or inflammatory environments when the extracellular concentrations of
adenosine (1.6-fold increase, p < 0.05) are sufficient to activate the receptor. Inhibition of the A2B receptor under normoxic conditions therefore did not affect any parameter tested. Reciprocal positive regulation of HIF and the A2B receptor in a hypoxic microenvironment thus enhances glycolytic and mitochondrial metabolism in osteoclasts to drive increased
bone resorption. A2B receptor inhibition could potentially prevent the pathological
osteolysis associated with hypoxic diseases such as
rheumatoid arthritis.